Scholars Central

Mini reviewPublished 27 Jun 2024

Pharmacogenomics of Immune Checkpoint Inhibitors: Cellular Responses and Therapeutic Strategies

Authors: Andrea Stefania

Center for Natural and Human Sciences, Universite federale de l’ABC, Brazil

Journal of Cellular and Molecular Pharmacology

Volume 8 · Issue 3 · Pages 1–3

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by harnessing the immune system to target tumors, leading to durable responses in various malignancies. However, the efficacy of ICIs varies widely among patients, necessitating a deeper understanding of pharmacogenomics to optimize therapeutic outcomes.This abstract provides an overview of the cellular responses to ICIs and explores pharmacogenomic strategies aimed at enhancing treatment efficacy and overcoming resistance mechanisms. ICIs function by blocking inhibitory pathways, such as CTLA-4, PD-1, and PD-L1, thereby unleashing T-cellmediated anti-tumor immune responses. Variability in treatment response is influenced by genetic factors, including polymorphisms in immune checkpoint genes and tumor mutational burden (TMB), which affect immune recognition and response to therapy. Additionally, the gut microbiome composition and host immune profile play crucial roles in modulating treatment outcomes by influencing systemic immune activation and tumor microenvironment dynamics. Pharmacogenomic approaches to optimize ICI therapy include biomarker identification, such as PD-L1 expression and TMB, to stratify patients likely to benefit from treatment. Combination therapies with other immunomodulators or targeted agents aim to synergize immune responses and overcome resistance mechanisms. Genomic profiling and AI-driven analyses enable personalized treatment strategies based on individual patientcharacteristics and tumor biology.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Cellular and Molecular Pharmacology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Cellular and Molecular Pharmacology
  • SubjectPharmaceutical Sciences
  • SubjectGenetics & Molecular Biology
  • BylineArticles whose byline prints “Andrea Stefania”